SciELO - Scientific Electronic Library Online

 
vol.50 issue2Hypodermoclysis in patients presenting with terminal cancerUse of kidneys for renal transplant from donors aged 55 and over author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Cubana de Medicina

On-line version ISSN 1561-302X

Abstract

CHAVEZ MEDINA, Reysel et al. Clinical features and therapeutic results of primary mediastinal large B- cells non-Hodgkin's lymphomas. Rev cubana med [online]. 2011, vol.50, n.2, pp. 157-166. ISSN 1561-302X.

A retrospective, descriptive and observational study was conducted to assess the clinical-biological features and the therapeutic results of the primary mediastinal of large B cells lymphoma in 34 patients seen in the "Hermanos Ameijeiras" Clinical Surgical Hospital from June, 1989 to February, 2009. There was predominance of female sex (61.8 %), mean age of 31.5 years (19 to 61 years) and of white race (70.6 %). The localized stages were more frequent (67.7 %), without B symptoms (64.7 %) and with a large tumor mass (70.6 %). Global survival and the free of progression survival at five years were of 53.4 and 43.4 %, respectively. The global survival at three years of the patients treated with MACOPB/VACOPB, CHOP and R-CHOP was of 77.7; 30.4 and 100 %, respectively. It was proved that patients treated with MACOPB/VACOPB had better results than those treated with CHOP. Age-adjusted international prognostic rate was not a survival predictor. In multivariable analysis, the only survival predictor was the applied (CHOP versus MACOPB). The routine use of radiotherapy has neither a significant impact on the global survival nor on the free of progression survival at five years.

Keywords : No-Hodgkin primary mediastinal large B cells lymphoma.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License